3. Umbruch 4.4..2005 - Online Pot

146 R.E. Musty
Discussion
The data discussed in this review show there is converging evidence that the
CB 1 receptor system is involved in the control of anxiety. Many studies have
shown that both antagonists and agonists of the CB 1 receptor can produce anxiolytic
effects both in animals and humans. Particularly strong evidence is the
fact that CB 1-knockout mice are more anxious than wild-type mice The fact
that anandamide hydrolysis inhibitors are anxiolytic and that they lead to an
increase in anandamide levels in the brain is further support for the role of this
system in the control of anxiety. Finally, the observations that CBD increases
or decreases regional cerebral blood flow in areas of the brain predicted to be
involved in various anxiety states provide strong supportive evidence that at
least this cannabinoid is active in brain areas known to be involved in anxiety.
At present, four cannabininoids are available for clinical trials: SR-141716
(Rimonbant), the GW Pharmaceuticals extract (Sativex ® ; a 1:1 ratio of
∆ 9 -THC/CBD), ∆ 9 -THC (Marinol) and Nabilone (Cesamet). It would seem
reasonable to consider testing these compounds in specific anxiety states,
which are refractory to traditional anxiolytics and related drugs.
References
1 McMeens RR (1860) Report of the Ohio State Medical Committee on Cannabis indica. Ohio State
Medical Society, White Sulphur Springs, OH, 59
2 Musty RE (1984) Possible anxiolytic effects of cannabidiol. In: S Agurell, W Dewey, R Willette
(eds): The Cannabinoids. Academic Press, New York, 829–844
3 Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in
the elevated plus-maze. Psychopharmacology 100: 558–559
4 Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of
natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and
antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1–PL6
5 Thomas BF, Gilliam AF, Burcj DF, Roche MJ, Seltzman HH (1998) Comparative receptor binding
analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285–292
6 Musty RE, Conti LH, Mechoulam R (1985) Anxiolytic properties of cannabidiol. In: D Harvey
(ed.): Marihuana 84. IRL Press, Oxford, 713–719
7 Rinaldi-Carmona M, Barth F, Heaulme, M, Alonso R, Shire D, Congy C, Soubrie P, Breliere JC,
Le Fur G (1995) Biochemical and pharmacological characterisation of SR141716A, the first
potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941–1947
8 Onaivi ES, Babatunde EA, Chakrabarti A (1998) Cannabinoid (CB 1) receptor antaginism induces
anxiolysis. 1998 Symposium on the Cannabinoids Burlington,VT: International Cannabinoid
Research Society, 58
9 Rodgers RJ, Haller J, Halasz J, Mikics E (2003) ‘One-trial sensitization’ to the anxiolytic-like
effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J
Neurosci 17: 1279–1286
10 Valjent E, Maldonado R (2000) A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol
in mice. Psychopharmacology (Berl) 147: 436–438
11 Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de
Fonseca F (1997) Acute administration of the CB 1 cannabinoid receptor antagonist SR 141716A
induces anxiety-like responses in the rat. Neuroreport 20; 8(2): 491–496
12 Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Psychopharmacology (Berl)
159: 379–387
13 Rodgers RJ, Haller J, Halasz J, Mikics E (2003) ‘One-trial sensitization’ to the anxiolytic-like